VCP Inhibition Augments NLRP3 Inflammasome Activation
Inflammation · 2024
DOI: 10.1007/s10753-024-02013-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammation, 2024. Verfasst von Ankita Sharma und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hope Center for Neurological Diseases, Washington University School of Medicine, St. Louis, MO, 63110, USA. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes, Valosin Containing Protein, Lysosomes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIAMS NIH HHS.
Abstract (Originalsprache)
Lysosomal membrane permeabilization caused either via phagocytosis of particulates or the uptake of protein aggregates can trigger the activation of NLRP3 inflammasome- an intense inflammatory response that drives the release of the pro-inflammatory cytokine IL-1β by regulating the activity of CASPASE 1. The maintenance of lysosomal homeostasis and lysosomal membrane integrity is facilitated by the AAA+ ATPase, VCP/p97 (VCP). However, the relationship between VCP and NLRP3 inflammasome activity remains unexplored. Here, we demonstrate that the VCP inhibitors, DBeQ and ML240 elicit the activation of NLRP3 inflammasome in bone marrow-derived macrophages (BMDMs) when used as activation stimuli. Moreover, genetic inhibition of VCP or VCP chemical inhibition enhances lysosomal membrane damage and augments LLoME-associated NLRP3 inflammasome activation in BMDMs. Similarly, VCP inactivation also augments NLRP3 inflammasome activation mediated by aggregated alpha-synuclein fibrils and lysosomal damage. These data suggest that VCP is a participant in the complex regulation of NLRP3 inflammasome activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Hope Center for Neurological Diseases, Washington University School of Medicine, St. Louis, MO, 63110, USA.
- Department of Neurology, Hope Center for Neurological Diseases, Washington University School of Medicine, St. Louis, MO, 63110, USA. weihlc@wustl.edu.
Förderung
- NIA NIH HHS
- NINDS NIH HHS
- NIAMS NIH HHS
- NIH HHS
- National Institute on Aging
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institutes of Health
Zitieren
APA
Sharma, A., Dhavale, D. D., Kotzbauer, P. T., & Weihl, C. C. (2024). VCP Inhibition Augments NLRP3 Inflammasome Activation. Inflammation. https://doi.org/10.1007/s10753-024-02013-6
Vancouver
Sharma A, Dhavale DD, Kotzbauer PT, Weihl CC. VCP Inhibition Augments NLRP3 Inflammasome Activation. Inflammation. 2024. doi:10.1007/s10753-024-02013-6
BibTeX
@article{Sharma2024,
author = {Sharma, Ankita and Dhavale, Dhruva D and Kotzbauer, Paul T and Weihl, Conrad C},
title = {VCP Inhibition Augments NLRP3 Inflammasome Activation},
journal = {Inflammation},
year = {2024},
doi = {10.1007/s10753-024-02013-6}
}
EUVIMED